Vaxart shares are trading higher after the company received a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study evaluating its COVID-19 oral pill vaccine candidate.
Portfolio Pulse from Benzinga Newsdesk
Vaxart shares are trading higher after the company received a BARDA-funded Project NextGen award valued up to $453 million to conduct a Phase 2b study evaluating its COVID-19 oral pill vaccine candidate.
June 14, 2024 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart shares are trading higher after receiving a BARDA-funded Project NextGen award valued up to $453 million for a Phase 2b study of its COVID-19 oral pill vaccine candidate.
The significant funding from BARDA for the Phase 2b study of Vaxart's COVID-19 oral pill vaccine candidate is a strong positive signal. This financial backing not only validates the potential of Vaxart's technology but also provides substantial resources for further development, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100